Zdravka MedarovaFounder & CTO at TransCode TherapeuticsSpeaker
Profile
Zdravka Medarova, PhD has served as Scientific Co-founder and a member of the advisory board of TransCode since January 2016. Dr. Medarova has been on the Faculty of Harvard Medical School and MGH since Jne 2007. She has served as an Associate Professor of Radiology at Harvard Medical School from April 2016 and as an Assistant in neuroimaging at the Athinoula A. Martinos Center for biomedical Imaging at MGH since June 2007. Dr. Medarova joined TransCode fulltime as the Chief Technology Officer on October 1, 2021. Dr. Medarova is a geneticist/ cancer biologist by training and is internationally recognized for her work on non-coding RNA for cancer therapy. She is one of the first to describe the design and application of nanoparticles as carries of siRNA to tumors. Dr. Medarova obtained a B.A. in pre medicine from the University of South Maine in September 1998 and a Ph.D. in Genetics from the University of New Hampshire in December 2001.
Agenda Sessions
A First-in-Class Therapy Against Metastatic Cancer: From Pre-Clinical Testing to Early Clinical Trials
, 13:45View Session